Benproperine Phosphate
CAS number： 19428-14-9
Molecular formula： C21H30NO5P
molecular weight： 407.44
Chemical structure：
Producers shown on SFDA
(Record date:29/09/2021）
Producer | Documents | GMP Valid till(based on SFDA) |
Jilin Jinheng Pharmaceutical Co., Ltd. | GMP | Valid till April 2021 |
Shanxi Xinbaoyuan Pharmaceutical Co., Ltd. | GMP | Valid till March 2020 |
hanxi Tongda Pharmaceutical Co., Ltd. | GMP | Valid till December 2019 |
Dalian Mingsen Pharmaceutical Co., Ltd. | GMP | Valid till March 2021 |
Dalian Wonful Pharmaceutical Co., Ltd. | GMP | Valid till May 2020 |
Jinzhou Jiutai Pharmaceutical Co., Ltd. | GMP | Valid till May 2022 |
Yunpeng Pharmaceutical Group Co., Ltd. | GMP | Valid till July 2020 |
Liaoyuan Baikang Pharmaceutical Co., Ltd. | GMP | Valid till July 2020 |
Shandong Xinyi Pharmaceutical Co., Ltd. | GMP | Valid till January 2019 |
Producers shown on EP
Not showing any
Jilin Hengjin Pharmaceutical Co., Ltd. is a key high-tech enterprise recognized by the state, with independent import and export management rights. At present, there are 343 kinds of preparation products and 23 varieties of synthetic drugs. It has many modern production lines such as solid preparations, oral liquid, powder injection, water injection and chemical API, all of which have passed the national GMP certification.
Staff size:200-299 persons
Registered capital:RMB 16.25 million
Producer:Shanxi Xinbaoyuan Pharmaceutical Co., Ltd. was established in 2004 with a registered capital of 100 million yuan and a total asset of 480 million yuan. It covers an area of about 130000 square meters. It is a comprehensive pharmaceutical enterprise integrating drug R & D, production and sales.
With advanced equipment and strong technical force, the company has a national production base of "methyl ester series" of antibiotic pharmaceutical intermediates and a complete industrial chain from raw materials to agent production based on independent research and development of "pectin". The product categories include pharmaceutical intermediates, oral APIs, isomorphic preparations, penicillin, etc., with more than 100 product approvals. Among them, 3 products have independent R & D patent certificates and enjoy exclusive patent use rights, and another 7 products have obtained national new drug certificates. The efficacy of the product covers many fields such as digestive system, pediatrics, respiratory system and local anesthesia.
Staff size:300-399 persons
Registered capital:RMB 100 million
Producer:Shanxi Tongda Pharmaceutical Co., Ltd. is a foreign-funded enterprise, formerly known as Shanxi Sanjiu Tongda Pharmaceutical Co., Ltd. the company covers an area of 60000 square meters and a construction area of 38000 square meters. It mainly produces five categories of products such as penicillin, cephalosporin, oral solid preparations, suppositories and API.
Staff size:200-299 persons
Registered capital:RMB 50 million
Producer:Dalian Mingsen Pharmaceutical Co., Ltd., established in 2012, has a complete and scientific quality management system. It is an enterprise certified by GMP, covering an area of 40 mu. It is the largest enterprise in China to produce sodium alginate diester, sodium balsalazide and benproperine phosphate API.
Staff size:50-99 persons
Registered capital:RMB 6 million
Producer:Dalian Wonful Pharmaceutical Co., Ltd., formerly known as Dalian Jinyi pharmaceutical factory, was established in 1987. The company covers an area of 20000 square meters and a construction area of 6000 square meters. At present, the phase II project is under construction, covering an area of 70000 square meters
Company owned There are 5 API codes and 25 preparation codes. In 2015, API passed the new national GMP certification. The company focuses on API and advanced intermediate products. The company has passed the audit of many international well-known enterprises. Its products are exported to Italy, Germany, France, South America, North America, India and other countries in the world.
Staff size:50-99 persons
Registered capital:RMB 90 million
Producer:Jinzhou Jiutai Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical enterprise with a production history of more than 60 years. The predecessor of Jinzhou No. 1 pharmaceutical factory was founded in 1951 and restructured into Jinzhou Jiutai Pharmaceutical Co., Ltd. in 1998. In recent years, various economic indicators have been among the top 100 pharmaceutical production enterprises in China. It is one of the key pharmaceutical enterprises in Liaoning Province.
The company covers an area of 58000 square meters, has a registered capital of 40.46 million yuan and has 1250 employees, including 310 engineering and technical personnel; It has 5 production workshops, 1 R & D center and 1 holding pharmaceutical commercial company. The company produces nearly 100 varieties, with reasonable product structure and good economic operation. Advanced production technology, mature process route, complete quality monitoring system and stable and reliable product quality.
Staff size:About 1250 persons
Registered capital:RMB 40.46 million
Producer:Yunpeng Pharmaceutical Group Co., Ltd. was established in 1998. It mainly produces and develops tablets, capsules, granules and injections, all of which have passed GMP certification. It has 9 subsidiaries and 1 branch with total assets of 1.2 billion yuan. At present, norfloxacin, indomethacin and mexiletine hydrochloride have been registered in India, and indomethacin has been registered in Russia, Mexico, Egypt, South Korea and other places. In Japan, mexiletine hydrochloride and vitamin U have also been reviewed by JDMF.
Staff size:300-399 persons
Registered capital:RMB 200 million
Producer:Liaoyuan Baikang Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Chongqing Sansheng Industrial Co., Ltd. Its predecessor, Liaoyuan No. 1 pharmaceutical factory, was founded in 1958.
After more than 50 years of accumulation and development, the company now has 104 drug production approval numbers, including 20 APIs and 84 preparations. The leading varieties of API are acetaminophen, chlorpipetin hydrochloride, nefopam hydrochloride, procaine hydrochloride, diphenhydramine hydrochloride, famotidine, dioxpromazine hydrochloride and levofloxacin mesylate. The annual output of preparations is more than 2 billion tablets, mainly including chlorpipetin hydrochloride tablets and compound paracetamol diphenhydramine tablets. The company has import and export rights, and its products are mainly exported to India, Hong Kong, Macao, Taiwan and other countries and regions. The company has passed GMP certification and COS certification, and is applying for FDA certification to obtain a pass for products to enter the European and American markets.
Staff size:About 400 persons
Registered capital:RMB 50 million
Producer:Shandong Xinyi Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical enterprise integrating manufacturing, sales and R & D, jointly funded by Shanghai Xinyi Pharmaceutical Factory Co., Ltd., a wholly-owned subsidiary of Shanghai Pharmaceutical Group Co., Ltd., Shandong Pingyuan pharmaceutical factory and Dezhou Borun Pharmaceutical Technology Co., Ltd.
Staff size:200-299 persons
Registered capital:RMB 17740.615851 million
For supply and market information, please feel free to contact Mr. Paul, paulzhang@yinuopharmchem.com, WhatsApp: +86 18402846978
Tel: Cell/WhatsApp/WeChat: +86 18402846978
Email: paulzhang@yinuopharmchem.com
SKYPE